Yearly STL Archives: 2020
Pediatric Psoriasis Comorbidities
While the association between psoriasis and various comorbidities is well documented in adults, questions remain as to whether the same relationships exist in the pediatric population.
Nicotinamide: An Update and Review of Safety & Differences from Niacin
Oral nicotinamide is an affordable over-the-counter supplement with demonstrated benefit in the treatment of a range of skin conditions, most notably AK and NMSC.
Update on Drugs & Devices: November – December 2020
This update covers: Gene therapy for DEB (AGLE-102), Golimumab for IV use (Simponi® Aria™), Clascoterone 1% cream (Winlevi®), Triplet melanoma therapy (Tecentriq® + Cotellic® and Zelboraf®), Ustekinumab for SC use (Stelara®), Calcipotriene + betamethasone dipropionate cream (Wynzora®), Abametapir 0.74% lotion (Xeglyze™), Sonidegib capsules (Odomzo®) and Halobetasol propionate + tazarotene lotion (Duobrii™).
The Impact and Treatment of Psoriasis in Manitoba Dermatology Clinics: The Case for Calcipotriol-Betamethasone Dipropionate Foam Formulation
In a small real-world patient case review study, dermatologists tested the efficacy, safety and patient preference of Enstilar®, a calcipotriol-betamethasone dipropionate (Cal/BD).
Trifarotene: A New Topical Retinoid for the Treatment of Acne Vulgaris
A new topical retinoid, trifarotene, the first fourth-generation retinoid, is now available in Canada for the treatment of moderate facial and truncal acne.
Colloidal Oatmeal use in Dermatology
Patients often seek natural approaches to treating skin disease. Colloidal oatmeal has been used for decades to improve atopic dermatitis and soothe other pruritic and xerotic dermatologic conditions.
Colloidal Oatmeal use in Dermatology (Supplement)
There is mounting evidence that colloidal oatmeal can safely enhance skin hydration and even help resolve clinical lesions through anti-inflammatory effects and by modulation of the microbiome.
Dermatologic Applications and Safety Considerations of Janus Kinase Inhibitors
Janus kinase inhibitors, also known as JAK inhibitors or jakinibs, represent a new class of medication that have broad potential to treat dermatologic disease.
Elective Treatment of Dermatosis Papulosa Nigra: A Review of Treatment Modalities
Dermatosis papulosa nigra is a benign skin lesion found most frequently on the face of patients with skin of color. This article compares treatment modalities for DPN.
Update on Drugs & Devices: September-October 2020
This update covers: Guselkumab SC use (Tremfya®), Adalimumab-fkjp SC use (Hulio®), Collagenase clostridium histolyticum-aaes SC use (Qwo™), Protein replacement therapy for XLHED (ER-004), Pembrolizumab IV use (Keytruda®), Minocycline 1.5% foam (Zilxi™), Microbiome-based non-aqueous ointment (ATR-12), Dupilumab SC use (Dupixent®) and Selumetinib capsules (Koselugo™)
The Role of Skin Care in Oncology Patients
The consensus paper aims to identify the impact on patients of skin toxicities associated with cancer treatment and evidence-based best practices for skincare to minimize or prevent these changes.
Risankizumab, an IL-23p19 Inhibitor for Psoriasis: A Review of the Current Literature
The addition of biologics that target IL-23p19 (Risankizumab) to our therapeutic armamentarium has succeeded in improving outcomes in patients with moderate-to-severe plaque psoriasis.
Management of Primary Small-Vessel Vasculitis
Small-vessel vasculitides (SVV) are a group of disorders that occur due to primarily systemic inflammation or as sequelae of an infection, malignancy, or other rheumatic disease.
Update on Drugs & Devices: May – June 2020
Update on Selumetinib capsules (Koselugo®), Crisaborole 2% ointment (Eucrisa®), Infliximab biosimilar for IV injection (Avsola™) and Baricitinib tablets (Olumiant®)
Use of Topical Crisaborole for Treating Dermatitis in a Variety of Dermatology Settings
The discussed cases reflect the panels’ real-world clinical experience with crisaborole for the treatment of patients with AD and the off-label treatment of irritant dermatitis.
A Novel Topical Retinoid for Acne: Trifarotene 50 μg/g Cream
In two large randomized vehicle-controlled 12-week trials and in a 52-week open label study of moderate-to-severe acne at the face and trunk in subjects aged 9 years and older, trifarotene 50 μg/g cream demonstrated efficacy, safety, and cutaneous tolerability.
An Anti-Wrinkle Diet: Nutritional Strategies to Combat Oxidation, Inflammation and Glycation
A number of research studies have documented the link between diet and skin aging. These results may be used to develop dietary recommendations that combat the forces of oxidation, inflammation, and glycation.
Skin Treatments Introduced in 2019
A variety of new skin treatments introduced in 2019.
Update on Drugs & Devices: March – April 2020
This update covers Tazemetostat tablets/Tazverik™ (Epizyme, Inc.), Tazarotene lotion 0.045%/Arazlo™ (Ortho Dermatologics, Bausch Health) and Rituximab biosimilar for IV injection/ABP 798 (Amgen, Allergan).
Hydrogen Peroxide Topical Solution, 40% (w/w) for the Treatment of Seborrheic Keratoses: A Review
Given our current options for the treatment of Seborrheic Keratoses include only more invasive, non-topical therapies, Hydrogen Peroxide Topical Solution (40%) fills a void in our therapeutic repertoire as the first FDA-approved topical therapy for SKs.
Management of Ichthyosis: A Brief Review
Ichthyosis management requires a multimodal approach, including topical and oral agents in addition to lifestyle modifications.
Update on Drugs & Devices: January – February 2020
This update covers Lebrikizumab SC injection (Dermira), Infliximab-axxq for IV injection (Avsola™, Amgen), Trifarotene cream 50 mcg/g (Aklief®, Galderma), Adalimumab-afzb for SC injection (Abrilada™, Pfizer), Lidocaine + tetracaine (7%/7%) local anesthetic cream (Pliaglis®, Crescita Therapeutics), Maralixibat oral solution (Mirum Pharmaceuticals), Cetirizine hydrochloride for IV injection (Quzyttir™, TerSera Therapeutics) and Minocycline foam 4% (Amzeeq™, Foamix)
Index for STL Volume 24 (2019)
Index of STL articles for Volume 24 (2019). Articles are indexed by drug names, trade names and disease terms. Use the main navigation (A, B, C..) to navigate through this index and use the reference links (i.e. 4:5-9) to see the sources.